Latest news with #IBRX
Yahoo
5 days ago
- Business
- Yahoo
ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield
ImmunityBio (IBRX) announced that the U.S. Food and Drug Administration, FDA, has granted Expanded Access authorization for the use of its Cancer BioShield platform, anchored by ANKTIVA, to treat lymphopenia in adult patients with refractory or relapsed solid tumors independent of tumor type who have progressed after first-line standard-of-care treatment, chemotherapy, radiation, or immunotherapy. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on IBRX: Disclaimer & DisclosureReport an Issue ImmunityBio to launch Cancer BioShield in the Middle East Piper upgrades ImmunityBio on Anktiva expansion opportunities ImmunityBio upgraded to Overweight from Neutral at Piper Sandler Short Report: Bears not fearing rebound in Rocket, Avis Budget shares ImmunityBio Sees Revenue Surge Amid Strong Sales Momentum
Yahoo
23-05-2025
- Business
- Yahoo
Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT
On May 20, Piper Sandler analyst Ed Tenthoff upgraded ImmunityBio Inc. (NASDAQ:IBRX) stock from Neutral to Overweight, raising the price target from $4.25 to $5.00. In a research note, the analyst told investors that the rating is based on the development of the company's ANKTIVA, t-haNK & M-ceNK cell therapies, and DNA vaccines, which combat cancer by supporting the immune system. ANKTIVA, for non-muscle invasive bladder cancer, is attaining a strong position in the market, with a 2025 sales forecast of $83.5 million. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. The rating came after ImmunityBio Inc. (NASDAQ:IBRX) reported strong fiscal Q1 2025 results on May 12, with the net product revenue reaching approximately $16.5 million. This translates to a 129% growth over $7.2 million in fiscal Q4 2024. ANKTIVA unit sales volume in the quarter also underwent a notable 150% rise over fiscal Q4 2024, with monthly volume in March growing 69% compared to February. Although the FDA's Refusal to File (RTF) letter for ANKTIVA in BCG unresponsive papillary NMIBC was a setback, Piper Sandler sees opportunity for ImmunityBio Inc. (NASDAQ:IBRX) as it is initiating the Phase III QUILT-2.005 trial in BCG naive NMIBC and expects to announce data in the coming year. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IBRX and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
23-05-2025
- Business
- Yahoo
Why ImmunityBio, Inc. (IBRX) Crashed Today
We recently published a list of . In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other firms that are drenched in red today. Ten companies pulled back on Wednesday, booking hefty losses during the trading session, with investor sentiment weighed down by a flurry of government policies and dismal earnings performance in the last quarter of the year. Meanwhile, the Dow Jones fell by 1.91 percent, the S&P 500 declined by 1.61 percent, and the tech-heavy Nasdaq dropped 1.41 percent. In this article, let us take a look at the 10 companies that led a poor performance during the day and explore the reasons behind their drop. To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million in trading volume. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. ImmunityBio saw its share prices decline by 8.62 percent on Wednesday to end at $2.65 apiece as investors sold off positions amid the lack of fresh catalysts, coupled with a market expert's sour comments on its stock. In the Monday episode of Mad Money, host and former hedge fund manager Jim Cramer said that ImmunityBio, Inc. (NASDAQ:IBRX) was 'not a great stock.' 'Immunity Bio—I've looked at it for a very, very long time. I don't like the fact that … they've been losing money forever. I am not in their camp,' he said. In contrast, another analyst posted a bullish stance on ImmunityBio, Inc.'s (NASDAQ:IBRX) stock. Piper Sandler, for its part, upgraded its rating for the company to 'overweight' from 'neutral' and raised its price target to $5 from $4.25 previously. It said that its rating reflected ImmunityBio, Inc.'s (NASDAQ:IBRX) Anktiva, t-haNK, and M-ceNK cell therapies, and DNA vaccines aimed at reactivating the immune system to fight cancer, which have shown a strong performance. Overall, IBRX ranks 6th on our list of firms that are drenched in red today. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than IBRX but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
22-05-2025
- Business
- Yahoo
Why ImmunityBio, Inc. (IBRX) Crashed Today
We recently published a list of . In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other firms that are drenched in red today. Ten companies pulled back on Wednesday, booking hefty losses during the trading session, with investor sentiment weighed down by a flurry of government policies and dismal earnings performance in the last quarter of the year. Meanwhile, the Dow Jones fell by 1.91 percent, the S&P 500 declined by 1.61 percent, and the tech-heavy Nasdaq dropped 1.41 percent. In this article, let us take a look at the 10 companies that led a poor performance during the day and explore the reasons behind their drop. To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million in trading volume. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. ImmunityBio saw its share prices decline by 8.62 percent on Wednesday to end at $2.65 apiece as investors sold off positions amid the lack of fresh catalysts, coupled with a market expert's sour comments on its stock. In the Monday episode of Mad Money, host and former hedge fund manager Jim Cramer said that ImmunityBio, Inc. (NASDAQ:IBRX) was 'not a great stock.' 'Immunity Bio—I've looked at it for a very, very long time. I don't like the fact that … they've been losing money forever. I am not in their camp,' he said. In contrast, another analyst posted a bullish stance on ImmunityBio, Inc.'s (NASDAQ:IBRX) stock. Piper Sandler, for its part, upgraded its rating for the company to 'overweight' from 'neutral' and raised its price target to $5 from $4.25 previously. It said that its rating reflected ImmunityBio, Inc.'s (NASDAQ:IBRX) Anktiva, t-haNK, and M-ceNK cell therapies, and DNA vaccines aimed at reactivating the immune system to fight cancer, which have shown a strong performance. Overall, IBRX ranks 6th on our list of firms that are drenched in red today. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than IBRX but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
Why ImmunityBio, Inc. (IBRX) Surged Last Week
We recently published a list of . In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other stocks that surged yesterday. Wall Street's main indices were a mixed bag anew on Thursday, with the tech-heavy Nasdaq the sole loser, as investors continued to digest results of more corporate earnings and key economic data. The Nasdaq was down by 0.18 percent. In contrast, the Dow Jones grew by 0.65 percent while the S&P 500 rose by 0.41 percent. Beyond the major indices, 10 companies finished stronger on the back of impressive corporate earnings and planned mergers and acquisitions. In this article, we explore the specific reasons behind their surge. To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million in trading volume. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. ImmunityBio rallied by 7.23 percent on Thursday to end at $2.67 apiece following a strong earnings performance and ratings upgrade from investment companies. In its earnings release, ImmunityBio, Inc. (NASDAQ:IBRX) said it narrowed its net loss attributable to stockholders by 3.3 percent to $129.6 million from the $134.1 million registered in the same period last year, as revenues skyrocketed by 41,192 percent to $16.5 million from only $40,000 in the same period last year. The higher revenues were driven by the strong performance of its Anktiva, an immunotherapy treatment for non-muscle invasive bladder cancer (NMIBC). According to the company, it continues to experience steady growth as urologists increase their use of the said treatment. Following the results, two investment firms gave a 'buy' recommendation on its stock. It also earned an $8 price target from HC Wainwright and a $6 price target from BTIG. Overall, IBRX ranks 6th on our list of stocks that surged last week. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than IBRX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
